Lynparza (olaparib) - Merck (MSD), AstraZeneca
Lynparza: "Five-year follow-up data from the Phase 3 SOLO-1 trial showed LYNPARZA reduced the risk of disease progression or death by 67% and improved median PFS to 56 months vs. 13.8 months for placebo in BRCAm advanced ovarian cancer patients"; Ovarian cancer (Merck (MSD)) - Sep 22, 2020 - ESMO 2020 
P3 data Oncology • Ovarian Cancer
Sep 22, 2020